Eliglustat: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Eliglustat. Educational only — not medical advice.
Labeled uses
CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test [see Dosage and Administration (2.1) ] .
Source: FDA labeling via NIH DailyMed (set 819f828a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.